Immunogenicity and Safety of Inactivated Influenza Vaccine in Healthy Korean Children and Adolescent
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents
Abstract
Purpose: This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents. Methods: From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination. Results: The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%). Conclusions: This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents
참고문헌 (31)
- Thompson WW, "Mortality associated with influenza and respiratory syncytial virus in the United States", JAMA, 289, pp.179~186 (2003)[DOI]
- Thompson WW, "Influenza-associated hospitalizations in the United States", JAMA, 292, pp.1333~1340 (2004)[DOI]
- Fiore AE, "Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009", MMWR Recomm Rep, 58(RR-8), pp.1~52 (2009)
- Cheong HJ, "Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis", Vaccine, 24, pp.2417~2422 (2006)[DOI]
- Fiore AE, "Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008", MMWR Recomm Rep, 57(RR-7), pp.1~60 (2008)
- [URL]
- [URL]
- Kim YK, "Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV) in South Korean children and adolescents: a randomized, double-blind, multi-center, phase 3 clinical trial", Open Forum Infect Dis, 3(Suppl 1), pp.S201~ (2016)
- Cintra OA, "Safety, immunogenicity and efficacy of influenza vaccine in children", J Pediatr (Rio J), 82(3 Suppl), pp.S83~S90 (2006)[DOI]
- Wright PF, "The use of inactivated influenza vaccine in children", Semin Pediatr Infect Dis, 17, pp.200~205 (2006)[DOI]
- Han SB, "Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial", Hum Vaccin Immunother, 11, pp.1094~1102 (2015)[DOI]
- [URL]
- [URL]
- Walter EB, "Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally?", Vaccine, 28, pp.4376~4383 (2010)[DOI]
- Seidman JC, "Quantitative review of antibody response to inactivated seasonal influenza vaccines", Influenza Other Respir Viruses, 6, pp.52~62 (2012)[DOI]
- Langley JM, "Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial", J Pediatric Infect Dis Soc, 1, pp.55~63 (2012)[DOI]
- Yang P, "Influenza vaccine effectiveness against medically-attended influenza illness during the 2012-2013 season in Beijing, China", Vaccine, 32, pp.5285~5289 (2014)[DOI]
- Song JY, "Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage", J Clin Virol, 38, pp.149~152 (2007)[DOI]
- Ahout I, "Influenza vaccination in kids, are you kidding me", J Infect, 68(Suppl 1), pp.S100~S107 (2014)[DOI]
- Heinonen S, "Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study", Lancet Infect Dis, 11, pp.23~29 (2011)[DOI]
- Blyth CC, "Effectiveness of trivalent flu vaccine in healthy young children", Pediatrics, 133, pp.e1218~e1225 (2014)[DOI]
- Kee SY, "Influenza vaccine coverage rates and perceptions on vaccination in South Korea", J Infect, 55, pp.273~281 (2007)[DOI]
- Jefferson T, "Vaccines for preventing influenza in healthy children", Cochrane Database Syst Rev, (2) (2008)
- Neuzil KM, "Influenza vaccines in children", Semin Pediatr Infect Dis, 13, pp.174~181 (2002)[DOI]
- McMahon AW, "Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003", Pediatrics, 115, pp.453~460 (2005)[DOI]
- Kanra G, "Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children", Pediatr Infect Dis J, 23, pp.300~306 (2004)[DOI]
- 조유미, "건강한 성인에서 인플루엔자 백신의 근육내 주사와 절반 용량 피부내 주사의 면역원성과 안전성 비교", Infection and Chemotherapy, 38(5), pp.259~265 (2006), 대한감염학회
- Greenberg ME, "Response to a monovalent 2009 influenza A (H1N1) vaccine", N Engl J Med, 361, pp.2405~2413 (2009)[DOI]
- al-Mazrou A, "Comparison of adverse reactions to whole-virion and splitvirion influenza vaccines in hospital personnel", CMAJ, 145, pp.213~218 (1991)
- Kim YK, "Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months", Scand J Infect Dis, 45, pp.460~468 (2013)[DOI]
- Masurel N, "Antibody response to immunization with influenza A", USSR, New Jersey, pp.76 (H1N1) virus, J Hyg (Lond)[DOI]